Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RA Risk Rises in Association With CCP Antibody Level

Key clinical point: The risk of progression to rheumatoid arthritis (RA) increased with rises in cyclic citrullinated peptide (CCP) antibody levels in CCP-positive adult patients.

Major finding: Over 1,047 person-years of follow-up, 73 patients (22%) developed rheumatoid arthritis, and 46% of patients with high levels of CCP antibodies developed rheumatoid arthritis within 5 years of entering the study.

Study details: The data come from a retrospective cohort study of 340 adults who were cyclic citrullinated peptide (CCP) antibody positive but without RA at baseline.

Disclosures: The researchers had no financial conflicts to disclose.

Citation:

Ford JA et al. Arthritis Care Res. 2019 Dec;71(12):1583-92. doi: 10.1002/acr.23820